CDKN2A and melanoma: P16 may be inactivated by homozygous deletions [6] or methylation of the promoter region [7], and this phenomenon commonly occurs in families with melanoma aggregation [8], while CDKN2A mutations are registered less frequently in primary tumors associated with sporadic cases [9].